Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
106
Active, not recruiting, industry sponsors, Cardiovascular and metabolic, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting193
- Completed2,436
106 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06307652 · 4,005 participants · Start Apr 12, 2024 · Primary completion Apr 16, 2027
Drug: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg; balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg and 1 more · For: Heart Failure and Impaired Kidney Function
Sites: Alexander City, Alabama; Fairhope, Alabama; Huntsville, Alabama · 676 sites in all
- Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesPivotal-lookingActive, not recruiting
KaileraIndustry
NCT07284901 · 1,270 participants · Start Jan 12, 2026 · Primary completion Mar 27, 2028
Drug: Ribupatide; Placebo · For: Obesity With Diabetes; Overweight With Diabetes
Sites: Cullman, Alabama; Phoenix, Arizona; Sun City, Arizona · 174 sites in all
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06297603 · 341 participants · Start Mar 15, 2024 · Primary completion Oct 26, 2026
Drug: Retatrutide; Placebo · For: Type 2 Diabetes
Sites: Huntsville, Alabama; Sun City West, Arizona; Apple Valley, California · 76 sites in all
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT04153149 · 655 participants · Start Nov 26, 2019 · Primary completion May 8, 2024
Drug: Vutrisiran; Sterile Normal Saline (0.9% NaCl) · For: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Sites: La Mesa, California; Los Angeles, California; Stanford, California · 121 sites in all
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04775082 · 82 participants · Start Mar 4, 2021 · Primary completion Aug 1, 2023
Drug: Liraglutide; Placebo · For: Obesity
Sites: Tucson, Arizona; Denver, Colorado; Meridian, Idaho · 32 sites in all
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintidePivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07220759 · 330 participants (planned) · Start Nov 5, 2025 · Primary completion May 12, 2027
Drug: Cagrilintide; Placebo (matched to Cagrilintide) · For: Overweight; Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Montgomery, Alabama; Tucson, Arizona · 67 sites in all
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseasePivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05030428 · 17,004 participants · Start Nov 23, 2021 · Primary completion May 10, 2027
Drug: Inclisiran sodium 300 mg; Placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 989 sites in all
- Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle GlaucomaPivotal-lookingActive, not recruiting
Omikron Italia S.r.l.Industry
NCT05710198 · 873 participants · Start Dec 11, 2023 · Primary completion Jul 1, 2029
Drug: Citicoline eye drops 2%; Placebo · For: Glaucoma, Open-Angle
Sites: Milan, Italy
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05556512 · 15,374 participants · Start Oct 11, 2022 · Primary completion Oct 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 672 sites in all
- AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07400107 · 985 participants · Start May 20, 2026 · Primary completion Dec 19, 2028
Drug: NNC0487-0111; Semaglutide and 2 more · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Hollywood, Florida; Orange City, Florida; Weston, Florida · 122 sites in all
- A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07232719 · 250 participants (planned) · Start Nov 17, 2025 · Primary completion Jun 2027
Drug: Retatrutide; Placebo · For: Obesity; Overweight
Sites: Riverside, California; Atlantis, Florida; Orlando, Florida · 31 sites in all
- A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential HypertensionPivotal-lookingActive, not recruiting
THPharm Corp.Industry
NCT06647745 · 222 participants · Start Apr 10, 2025 · Primary completion Nov 4, 2026
Drug: THP-00101; THP-00102 and 4 more · For: Type 2 Diabetes; Hypertension
Sites: Seoul, South Korea; Pathum Thani, Thailand
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07000136 · 473 participants · Start Jun 10, 2025 · Primary completion Jan 4, 2027
Drug: AZD0780; Placebo · For: Heterozygous Familial Hypercholesterolaemia
Sites: Garden Grove, California; San Diego, California; Miami Lakes, Florida · 133 sites in all
- EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardiomyopathyPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06194825 · 64 participants · Start Dec 1, 2023 · Primary completion May 13, 2026
Drug: Eplontersen; Placebo · For: Transthyretin Amyloid Cardiomyopathy
Sites: Beijing, China; Changsha, China; Chengdu, China · 26 sites in all
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07533175 · 638 participants (planned) · Start Apr 13, 2026 · Primary completion Aug 7, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Diabetes Mellitus; Overweight; Obesity
Sites: Birmingham, Alabama; Escondido, California; Lomita, California · 73 sites in all
- UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)Pivotal-lookingActive, not recruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07648225 · 600 participants (planned) · Start Sep 4, 2026 · Primary completion Sep 29, 2027
Drug: UBT251 Injection 4.0 mg; UBT251 Injection 6.0 mg and 2 more · For: Obesity & Overweight
Sites: Beijing, China
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05739383 · 14,012 participants · Start Mar 9, 2023 · Primary completion Apr 16, 2029
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Placebo in 1.5ml · For: Primary Prevention of Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 983 sites in all
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) TherapyPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06994650 · 144 participants · Start Aug 13, 2025 · Primary completion Dec 2026
Drug: HRS9531; Placebo · For: Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
Sites: Beijing, China
- Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionPivotal-lookingActive, not recruiting
Mineralys Therapeutics Inc.Industry
NCT05968430 · 1,076 participants · Start Jul 14, 2023 · Primary completion Dec 30, 2025
Drug: lorundrostat; Placebo · For: Hypertension
Sites: Birmingham, Alabama; Foley, Alabama; Chandler, Arizona · 177 sites in all
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04175600 · 138 participants · Start Jan 16, 2020 · Primary completion Oct 11, 2024
Drug: Selexipag; Placebo and 3 more · For: Hypertension, Pulmonary
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 116 sites in all
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05757869 · 20,284 participants · Start Apr 11, 2023 · Primary completion Dec 8, 2026
Drug: Milvexian; Apixaban and 2 more · For: Atrial Fibrillation
Sites: Alexander City, Alabama; Birmingham, Alabama; Dothan, Alabama · 1,052 sites in all
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04273945 · 935 participants · Start Jun 30, 2020 · Primary completion Oct 7, 2025
Drug: Macitentan 10 mg; Macitentan 37.5 mg and 2 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 274 sites in all
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesPivotal-lookingActive, not recruiting
vTv TherapeuticsIndustry
NCT06334133 · 150 participants (planned) · Start Jun 14, 2024 · Primary completion Apr 2027
Drug: Cadisegliatin 800 mg QD; Cadisegliatin 800 mg BID and 1 more · For: Diabetes Mellitus, Type 1
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Concord, California · 48 sites in all
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT07037433 · 12,800 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 30, 2028
Drug: Maridebart Cafraglutide; Placebo · For: Atherosclerotic Cardiovascular Disease; Overweight; Obesity
Sites: Daphne, Alabama; Fairhope, Alabama; Huntsville, Alabama · 783 sites in all
- A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyPivotal-lookingActive, not recruiting
BayerBayer (BAYRY)
NCT07023341 · 36 participants · Start Jun 30, 2025 · Primary completion Jul 14, 2026
Drug: BAY3723113 · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Kurume, Japan; Himeji, Japan; Kobe, Japan · 23 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.